 Organogenesis Holdings Inc NASDAQ: ORGO Q2 revenues increased 79 YY to 123.2 million, edging out analysts average expectation of 107.30 million. The increase was driven by a 51.7 million increase, or 87, in net revenue of Advanced Wound Care products and a 2.5 million growth, or 27, in net revenue of Surgical Sports Medicine products. 